Reports Q2 revenue $212.802M, consensus $162.17M. Bill Sibold, Chief Executive Officer of Madrigal, stated: “We’ve delivered another exceptional quarter driven by continued strong Rezdiffra demand. Additionally, we continued to execute on our strategy by securing a new U.S. patent extending Rezdiffra’s patent protection to 2045; advancing our pipeline with an oral GLP-1 development candidate; preparing to enter Europe following a positive CHMP opinion; presenting compelling new two-year data in F4c; and strengthening our balance sheet with access to up to $500 million in non-dilutive capital. I’m incredibly proud of the team’s execution and the progress we’ve made.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- MDGL Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Madrigal Pharmaceuticals Signs Global License Agreement
- Madrigal Pharmaceuticals enters license pact with CSPC for SYH2086
- Madrigal Pharmaceuticals: Strengthened Financial Position and Promising Pipeline Expansion Drive Buy Rating
- Madrigal Pharmaceuticals: Strategic Financing and Growth Potential Justify Buy Rating